Overview

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

Status:
Completed
Trial end date:
2020-07-28
Target enrollment:
Participant gender:
Summary
Double blind, randomized, placebo controlled, Phase 3 study to investigate the efficacy and safety of low doses and high doses of A4250 compared to placebo in children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2.
Phase:
Phase 3
Details
Lead Sponsor:
Albireo